MA201 2022

Wednesday September 21st and Thursday September 22nd, 2022

CAHR Member - 2 Half Days: $695+tax | Non-Member - 2 Half Days: $995+tax
CAHR Member - 1 Half Day: $395+tax | Non-Member 1 Half Day: $595+tax Limited number of special discounts available to patient groups and students. Please contact the CAHR office for information.

******************************************************************

Please note: if you're working towards your CMAP Certification you MUST attend both half days of the program.

The only constant in life is change, but this moment feels especially transformative for Canadian healthcare generally, and particularly for market access. As we scramble to make sense of the pandemic and plan for an eventual return to normal, transformative new medicines are coming to market, often with significant information demands and potentially requiring additional investments in infrastructure. These new treatments may also force us to rethink the nature of evidence, with a greater emphasis on life-cycle management and health technology management. Our faculty will discuss the implications of these and other challenges facing market access professionals and provide insights and direction for navigating the evolving frontier of market access.

Day 1: Cell & Gene Technologies

C&G therapies represents an important emerging field of research and commercial product launches.  Several companies have strong pipelines of C&G technologies, but the entire field remains somewhat mysterious to most. Sophisticated biomarker testing, up to and including Next-Generation Sequencing/whole-genome sequencing, is almost certainly a prerequisite for the feasibility of the introduction of these new technologies, but access remains poorly defined or understood.  The objective of today’s agenda is to demystify the world of C&G therapies, to clarify how these products are being developed, brought to market and paid for.

Day 2: Preparing for the Future of Healthcare Reimbursement

The rate of change driven by advancements in biotechnologies, pandemic influences and fiscal restraint shows no signs of slowing. There are numerous initiatives that are ongoing and intended to support the need for thoughtful, patient-focused solutions.  Today’s agenda will consider the future of healthcare and discuss the different initiatives and perspectives that are driving the environment moving forward.